Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
about
KASL clinical practice guidelines: management of chronic hepatitis BNew virologic tools for management of chronic hepatitis B and CThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidationHepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityHepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective studyComparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.Natural Killer Cells in Viral Hepatitis.Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Evaluation of changes of serum hepatitis B surface antigen from a different perspective.How further suppression of virus replication could improve current HBV treatment.Hepatitis B virus genotypes and variants.Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment.Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.Chronic hepatitis B: what should be the goal for new therapies?Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.HBsAg Quantification in Clinical Practice.HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.Recent advances in the treatment of chronic hepatitis B.Hepatitis B surface antigen monitoring and management of chronic hepatitis B.Is there any value to hepatitis B virus genotype analysis?Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.Clinical implications of HBsAg quantification in patients with chronic hepatitis B.The role of HBsAg quantification for monitoring natural history and treatment outcome.Telbivudine treatment in chronic hepatitis B: experience from China.Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.
P2860
Q26752475-6E429B30-AE19-4A8E-9A57-730183CE3B2AQ27026914-193D1047-32B6-4D0B-A332-7A027D20597CQ28485228-D0D4DFEA-45BD-41A7-B3F0-AE1A820E9AD5Q30391932-FB081A24-7913-46A8-AE3B-2708A1F06578Q33845546-7331A56A-7704-4258-A05A-E364FDAB5EB4Q33875691-9F3D560C-A7E0-4B19-AFF0-8285DDBC84CEQ33911464-F29595E6-277F-4745-8DB8-C26F0E250CCEQ33958876-93F0B586-61BD-4391-91A4-E72C6B74B223Q34189348-008820DC-8A5E-4133-AED5-A5AABBB186AFQ34335676-B326C4DE-6995-4D7C-8FCD-66030345CD80Q34384793-0FD9854F-ADB5-4AF5-8AEA-B4E8BB3C1890Q34505690-AABF1192-97D7-4145-9299-782AE9945C41Q34509494-19FF416A-AB32-4610-97C0-967336BCF35BQ34592952-E02F6DD4-74DB-4637-9731-A95E533ECC46Q35152364-D0B19991-1DA2-48EA-96E2-8ED9904781BCQ35622347-AFCEA4EB-2EB1-4ADB-9622-8117FD7DEC01Q35663838-FC69F5FA-1A26-4AA9-A0CF-97C9A4055E83Q35671645-9014E722-4596-4A1D-9683-F32C85006617Q35739079-2C708941-1E46-48EA-8B80-B6CFEBD4C8F3Q35833216-3C062C21-F40D-4DF7-B7B7-980038F84421Q35973806-B5C7FC7F-A328-4177-890D-3E615A1236CFQ36067389-EA931B88-453C-4340-98A8-38D05C523BE6Q36073739-FA8B8E95-D525-417F-ACE6-8B7FAD510E96Q36220194-ED763CED-51D8-451A-8291-40529160C309Q36254363-B5FEC790-5DC4-42FF-A444-2D33B9F09815Q36745002-2FA33020-7E82-42F6-A8DF-7476CD2B1AE6Q36769986-8C0F38EC-31F2-4CB3-AAB7-89B593816CF0Q36797804-37BB59AE-2BE2-4DDC-9CCA-4848B3A94D5FQ36973383-0BA68433-6C53-42CB-A455-FB7602D52A0CQ37614037-175276BE-6330-46F2-A65D-E9185539C443Q37708054-3E55EE47-A7D9-45A7-963B-58CEE243C6DAQ37866717-4EDFC16A-6151-4E4B-B3A2-C412FB22F849Q37891094-C978C421-945D-449E-9D68-E7C892292499Q37892655-94FFE569-E760-4A17-B6A6-8B87AAF66C1DQ37959290-A5DD1FA6-7B93-4EE0-BE76-D6CED305C8B9Q37966704-5D56A87B-A986-4BFF-9500-514EE9DFB8B4Q37994049-22786696-C6DC-458F-8492-521FBF7A0C7CQ38071397-6FF3E47C-C64F-4FD5-BD78-97BD8A92C866Q38086311-4515277D-E7E2-4791-95D8-284692C36A19Q38086312-A0858E3B-8542-4FD5-834E-43DBAB84534A
P2860
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@en
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@nl
type
label
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@en
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@nl
prefLabel
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@en
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@nl
P2093
P356
P1433
P1476
Kinetics of hepatitis B surfac ...... B e antigen-positive patients.
@en
P2093
Heiner Wedemeyer
Karsten Wursthorn
Mechthild Jung
Michael P Manns
Nikolai V Naoumov
Patricia Lopez
Weibin Bao
Zachary D Goodman
P304
P356
10.1002/HEP.23905
P407
P50
P577
2010-11-01T00:00:00Z